Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Subscribe To Our Newsletter & Stay Updated
